celecoxib + isotretinoin + temozolomide + thalidomide

This is a combination regimen consisting of four small-molecule drugs, each with distinct mechanisms of action and primary indications, most commonly used in oncology or investigational settings. - **Celecoxib** is a selective cyclooxygenase-2 (COX-2) inhibitor, primarily used as an anti-inflammatory and analgesic agent. It has been investigated for its potential antineoplastic effects due to its ability to inhibit prostaglandin synthesis and modulate tumor microenvironment. - **Isotretinoin** is a retinoid (vitamin A derivative) that modulates cell differentiation and proliferation by activating retinoic acid receptors; it is mainly used for severe acne but also studied in cancer chemoprevention and treatment due to its effects on cell cycle arrest and apoptosis. - **Temozolomide** is an oral alkylating agent of the imidazotetrazine class that induces DNA damage by methylating guanine residues, leading to tumor cell death; it is approved for glioblastoma multiforme and refractory anaplastic astrocytoma[1][2][3][4]. - **Thalidomide** is an immunomodulatory agent with antiangiogenic properties, approved for multiple myeloma (with dexamethasone), erythema nodosum leprosum, and under investigation for other cancers; it acts through multiple mechanisms including inhibition of TNF-alpha production, modulation of immune response, suppression of angiogenesis via VEGF inhibition[6][8][10]. This specific four-drug combination does not have a unique brand name or established fixed-dose formulation but may be explored in clinical trials or off-label protocols targeting aggressive or refractory malignancies.